Xeris Biopharma Holdings, Inc.

    Jurisdiction
    United States
    ISIN
    US98422E1038 (XERS)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    6 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    5 / 7

    Profile

    Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. Read full profile

    Fundamentals

    Net revenue
    €209.85M
    Gross margin
    81.1%
    EBIT
    -€8.38M
    EBIT margin
    -4.0%
    Net income
    -€27.29M
    Net margin
    -13.0%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €297.41M +41.7% €33.38M -222.3%
    €346.98M +16.7% €52.32M +56.8%
    €403.64M +16.3% €93.74M +79.2%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    SHERMAN JEFFREY W N/A -42K $7.92 -$334.48K
    JOHNSON JOHN N/A -108K $7.32 -$786.90K
    HALKUFF DAWN N/A -43K $7.28 -$309.40K

    Earnings Calls

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 2.2M $11.87M +64K Buy

    Earnings Calls

    Latest earnings call: August 7, 2025 (Q2 2025)

    Add to watchlist

    Notifications